Sign in
Taking people in United KingdomPhase 1

Tests VVD-133214 alone or with other drugs in advanced solid tumors

Tests VVD-133214, a pill, in adults with advanced solid tumors.

Key facts

Who runs it
Vividion Therapeutics, Inc.
Where
Birmingham, Leeds, London, Manchester, and Sutton, United KingdomSee the 5 sitesAlso in 10 other countries, 52 sites
Registry title
A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors
Status
Recruiting
Phase
Phase 1
People taking part
280 people, planned
Started
25 Jan 2024
Expected to end
31 May 2027
Type of study
Interventional, 4 groups
Treatments tested
  • VVD-133214
  • Pembrolizumab
  • Bevacizumab
Record updated
12 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with an advanced solid tumor that has microsatellite instability (MSI) and/or deficient mismatch repair (dMMR). Some parts are for colorectal cancer.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Advanced (cannot be removed by surgery and/or has spread) solid tumor with MSI and/or dMMR, with disease that can be measured by RECIST version 1.1. The bevacizumab part is for advanced or metastatic colorectal adenocarcinoma. The pembrolizumab part is for locally advanced or metastatic colorectal cancer that cannot be treated with surgery.
Earlier treatment
Single-drug part: at least 2 standard treatment regimens for advanced disease, with the cancer progressing or the treatment not tolerated. Bevacizumab part: 2 to 3 prior lines of systemic therapy for advanced colorectal cancer. Pembrolizumab part: no earlier systemic treatment for metastatic disease. People who had a WRN helicase inhibitor cannot join.
Biomarker or test result
The tumor must have microsatellite instability (MSI) and/or deficient mismatch repair (dMMR). Stored tumor tissue is needed for central testing, or a new biopsy if none is available.

Main reasons for not taking part

  • Cannot swallow pills, or has a condition that affects absorption from the gut
  • Uncontrolled brain metastases or carcinomatous meningitis
  • Active or uncontrolled infection, or a positive test for hepatitis B, hepatitis C or HIV
  • Known Werner syndrome
  • Pregnant, breastfeeding, or planning to become pregnant during the study

The registry criteria, word for word

Show all 31 criteriaShow less

Who can take part

  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
  • Have a microsatellite instability (MSI) and/or deficient mismatch repair (dMMR), histologically or cytologically documented advanced (unresectable and/or metastatic) solid tumor
  • For monotherapy only (solid tumor): Have received and then progressed following or are intolerant to at least 2 standard treatment regimens in the advanced setting including standard chemotherapy or checkpoint inhibitors according to tumor type
  • For the combination with bevacizumab only: Advanced, or metastatic colorectal adenocarcinoma (CRC) treated with at least 2 but no more than 3 prior lines of systemic therapy for the treatment of advanced CRC and demonstrated progressive disease or intolerance to the last regimen. Prior treatment regimens must have included (unless not eligible for or intolerant to any of these agents): An immune checkpoint inhibitor (if available as standard of care), Fluoropyrimidine, Irinotecan and/or oxaliplatin, +/- an anti-VEGF monoclonal antibody, Participants with RAS WT tumors may have received anti-epidermal growth factor receptor (EGFR) monoclonal antibody based on Investigator discretion. Treatment with adjuvant/neoadjuvant chemotherapy and/or immunotherapy will count as a line of therapy for advanced disease if progression occurred during or within 12 months of completing the treatment
  • For the combination with pembrolizumab only: Histologically confirmed locally advanced, or metastatic CRC with no prior systemic treatment for metastatic disease and not amenable to surgery
  • Presence of measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
  • Life expectancy of at least (≥)12 weeks
  • Availability of formaldehyde-fixed paraffin-embedded (FFPE) archival tumor tissue for submission to Sponsor/central laboratory for retrospective central testing; for participants without archival tissue, a biopsy from either primary or metastatic tumor lesion, deemed medically feasible, must be taken
  • Adequate hematologic, end-organ, and cardiovascular function, as defined in the protocol

Who cannot take part

  • Known uncontrolled central nervous system (CNS) metastases (progressing or requiring anticonvulsants or corticosteroids for symptomatic control) and/or carcinomatous meningitis
  • Known active or uncontrolled bacterial, viral, fungal, mycobacterial (including but not limited to tuberculosis and atypical mycobacterial disease), parasitic, or other infection (excluding fungal infections of nail beds), or any major episode of infection requiring treatment with intravenous antibiotics or hospitalization within 2 weeks prior to the start of drug administration (related to the completion of the course of antibiotics, except if for tumor fever) or 6 months for any intracranial abscess
  • Significant cardiovascular/cerebrovascular disease within 6 months prior to Day 1 of study drug administration
  • Alcohol or drug dependence or abuse
  • Prior treatment with any WRN helicase inhibitor
  • Treatment with moderate or strong CYP3A4 inducers within 14 days prior to initiation of study treatment
  • Treatment with moderate or strong CYP3A4 or P-glycoprotein inhibitors within 14 days prior to initiation of study treatment
  • Pregnancy, breastfeeding, or intention of becoming pregnant during the study; Additional Exclusion Criteria for the Combination with Bevacizumab Only:
  • Had major surgery within 4 weeks prior to study drug administration
  • Deep venous thrombosis (DVT) or pulmonary embolism (PE) within 12 weeks prior to study drug administration
  • Treatment with systemic immunosuppressive medication (such as corticosteroids) within 2 weeks prior to initiation of study treatment with some exceptions
  • Treatment with organ transplant/graft tissue
  • Malabsorption syndrome or other condition that would interfere with enteral absorption
  • Has a positive test at screening for hepatitis B virus, hepatitis C virus, or for human immodeficiency virus (HIV), per local diagnostic standard and in accordance with local laws and regulations
  • Patients with known Werner (WRN) syndrome
  • Known coagulopathy that increases the risk of bleeding
  • Active or history of autoimmune disease or immune deficiency with some exceptions
  • History of interstitial lung disease or pneumonitis
  • Known hypersensitivity or intolerance to ingredients from the study drug formulation including patients with rare genetic disorders such as galactosaemia, glucose-galactose intolerance or congenital lactase deficiency
  • Uncontrolled diabetes or symptomatic hyperglycemia (i.e., well controlled defined as a screening hemoglobin A1c <8% and no urinary ketoacidosis)
  • Inability or unwillingness to swallow pills
  • Patients with Grade 2+ proteinuria (exception: if 24-hour urinary protein is less than 1.0 gm/24 hours); Additional Exclusion Criteria for the Combination with Pembrolizumab Only:

Where in United Kingdom

Also in 10 other countries, 52 sites

  • University Hospitals Birmingham NHS Foundation TrustBirmingham, United KingdomContact: Study DirectorNot yet recruiting
  • St James's Institute of OncologyLeeds, United KingdomContact: Study DirectorNot yet recruiting
  • Sarah Cannon Research InstituteLondon, United KingdomTaking people
  • The ChristieManchester, United KingdomTaking people
  • Royal Marsden Hospital (Sutton)Sutton, United KingdomTaking people

About the trial

What the trial wants to find out

This is a first-in-human, Phase I, open-label, multicenter, dose-escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of VVD-133214 monotherapy, and in combination with bevacizumab or pembrolizumab, in participants with microsatellite instability (MSI) and/or deficient mismatch repair (dMMR) advanced solid tumors. VVD-133214 is an oral drug that acts on a protein called Werner (WRN), which may promote the growth of cancers that are MSI and/or dMMR. By acting on WRN, VVD-133214 may be able to block the growth of these types of cancer.

The 4 groups in the trial

  • VVD-133214 Dose EscalationTreatment being tested

    Treatment: VVD-133214

  • VVD-133214 Monotherapy ExpansionTreatment being tested

    Treatment: VVD-133214

  • VVD-133214 + Pembrolizumab ExpansionTreatment being tested

    Treatment: VVD-133214 and Pembrolizumab

  • VVD-133214 + Bevacizumab ExpansionTreatment being tested

    Treatment: VVD-133214 and Bevacizumab

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
Official title
A Phase I, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors Harboring Microsatellite Instability (MSI) and/or Deficient Mismatch Repair (dMMR)
Plain-language title
Tests VVD-133214 alone or with other drugs in advanced solid tumorsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
12 November 2026